References
1. The Writing Committee Of The Report On Cardiovascular Health And Diseases In China. Hu SS. Report on cardiovascular health and diseases in China 2021: an updated summary. J Geriatr Cardiol 2023;20:399-430.
2. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017;390:2549-58.
3. Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
4. Hu C. C-type Hypertension. Eur Heart J 2019;40:715.
5. Hu C, Wu Y, Li J, et al. Hypertension associated with unhealthy lifestyle and marked by serum cortisol levels. Res Sq (preprint). 26 Aug, 2021. https://www.researchsquare.com/article/rs-824235/v1
6. Hu CS, Tkebuchava T. E-noise: An increasingly relevant health risk. J Integr Med 2019;17:311-4.
7. Hu C. Health is the first capital– A new concept from CHINA. Manuscript in Submission.
8. Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med 2023;389:1273-85.
9. Jafar TH, Islam M, Bux R, et al. Hypertension Research Group. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation 2011;124:1615-25.
10. McManus RJ, Little P, Stuart B, et al. HOME BP investigators. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ 2021;372:m4858.
11. Monahan M, Jowett S, Nickless A, et al. Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4). Hypertension 2019;73:1231-9.
12. Boubouchairopoulou N, Karpettas N, Athanasakis K, et al. Cost estimation of hypertension management based on home blood pressure monitoring alone or combined office and ambulatory blood pressure measurements. J Am Soc Hypertens 2014;8:732-8.
13. Kaambwa B, Bryan S, Jowett S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis. Eur J Prev Cardiol 2014;21:1517-30.
14. Søgaard R, Diederichsen ACP, Rasmussen LM, et al. Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS). Eur Heart J 2022;43:4392-402.
15. Li KC, Huang L, Tian M, et al. Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study. Circulation 2022;145:1534-41.
16. Henry A, Arnott C, Makris A, et al. Blood pressure postpartum (BP2) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy. Pregnancy Hypertens 2020;22:1-6.
17. Zomer E, Owen A, Magliano DJ, Liew D, Reid CM. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. BMJ 2012;344:e3657.
18. Zhang T, Liang Z, Lin T, et al. Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension. BMC Med 2022;20:407.
19. Maniadakis N, Ekman M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ 2011;12:253-61.
20. Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. Int J Clin Pract 2011;65:253-63.
21. Freeman MW, Halvorsen YD, Marshall W, et al. BrigHTN Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med 2023;388:395-405.
22. Laffin LJ, Rodman D, Luther JM, et al. Target-HTN Investigators. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA 2023;330:1140-50.
23. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med 2023;389:228-38.
24. Azizi M, Saxena M, Wang Y, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA 2023;329:651-61.
25. Fan J, Zheng W, Liu W, et al. Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China. Hypertension 2022;79:2631-41.
26. Derington CG, King JB, Bryant KB, et al. Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. Curr Hypertens Rep 2019;21:91.
27. Zhang Y, Yin L, Mills K, et al. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina. JAMA Netw Open 2021;4:e2122559.
28. Finkelstein EA, Krishnan A, Naheed A, et al. COBRA-BPS study group. Budget impact and cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension management programme in rural communities in Bangladesh, Pakistan, and Sri Lanka. Lancet Glob Health 2021;9:e660-7.
29. Augustovski F, Chaparro M, Palacios A, et al. Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina. Value Health 2018;21:1357-64.
30. Jafar TH, Tan NC, Allen JC, et al. Management of hypertension and multiple risk factors to enhance cardiovascular health in Singapore: The SingHypertension cluster randomized trial. Trials 2018;19:180.
31. Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott) 2017;150:184-97.
32. Penaloza-Ramos MC, Jowett S, Mant J, et al. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR). Eur J Prev Cardiol 2016;23:902-12.
33. Li T, Ding W, Li X, Lin A. Mobile health technology (WeChat) for the hierarchical management of community hypertension: protocol for a cluster randomized controlled trial. Patient Prefer Adherence 2019;13:1339-52.
34. Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc 2015;4:e001213.
35. Smith SM, Campbell JD. Cost-effectiveness of renin-guided treatment of hypertension. Am J Hypertens 2013;26:1303-1310.
36. Penaloza-Ramos MC, Jowett S, Barton P, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. Eur J Prev Cardiol 2016;23:1590-8.
37. Gu D, He J, Coxson PG, et al. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. PLoS Med 2015;12:e1001860.
38. Ma W, Sun N, Duan C, et al. for LEADER Study Group. Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. Cardiovasc Drugs Ther 2021;35:41-50.
39. Li C, Chen K, Cornelius V, et al. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. PLoS Med 2021;18:e1003515.
40. Ghazi L, Oparil S. Impact of the SPRINT Trial on Hypertension Management. Annu Rev Med 2018;69:81-95.
41. Oseran AS, Sun T, Wadhera RK. Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status. JAMA Cardiol 2022;7:708-14.
42. Berman AN, Biery DW, Ginder C, et al. Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol 2021;6:880-8.
43. Richman IB, Fairley M, Jørgensen ME, Schuler A, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of Intensive Blood Pressure Management. JAMA Cardiol 2016;1:872-9.
44. Lewey J, Murphy S, Zhang D, et al. Effectiveness of a Text-Based Gamification Intervention to Improve Physical Activity Among Postpartum Individuals With Hypertensive Disorders of Pregnancy: A Randomized Clinical Trial. JAMA Cardiol 2022;7:591-9.
45. Cao DY, Giani JF, Veiras LC, et al. An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo. Sci Transl Med 2021;13:eabj2138.
46. Xu X, Kawakami J, Millagaha Gedara NI, et al. Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance. Elife 2021;10:e70734.
47. Shen Q, Zhang H, Huang Y, et al. Sensitive detection of single-nucleotide polymorphisms by conjugated polymers for personalized treatment of hypertension. Sci Transl Med 2023;15:eabq5753.
48. Li X, Krumholz HM, Yip W, et al. Quality of primary health care in China: challenges and recommendations. Lancet 2020;395:1802-12.
49. Hu C, Wu Q. Health: a dream from reality to the future. Front Med 2016;10:233-5.
50. Hu CS. Intervention of RT-ABCDEF for cancer. Croat Med J 2019;60:55-7.
51. Hu C, Tkebuchava T. Health in All Laws: A better strategy for global health. J Evid Based Med 2022;15:10-4.